Lotus Pharmaceutical (1795) Stock Overview

Lotus Pharmaceutical Co., Ltd. research, develops, manufactures, and sells generic pharmaceutical products in Taiwan, Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system disease. The company also sells and markets a portfolio of over-the-counter medicines. In addition, it engages in wholesale of cosmetics; retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. The company has an agreement with NeuroRx Inc. to develop, manufacture, and commercialize NRX-101. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited.